Antimicrobial Resistance Diagnostics Market Size, Share, Demand & Report by 2034

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Antimicrobial Resistance Diagnostics Market Size Analysis

Global Antimicrobial Resistance Diagnostics Market Introduction
By Technology
1. Introduction
  1. Technology By Value
2. Microbial Culture
  1. By Value
3. Immunoassay
  1. By Value
4. Polymerase Chain Reaction
  1. By Value
5. Next-generation Sequencing
  1. By Value
6. Mass Spectrometry
  1. By Value
7. Others
  1. By Value
By Pathogen
1. Introduction
  1. Pathogen By Value
2. Methicillin-Resistant Staphylococcus Aureus
  1. By Value
3. Drug-Resistant Streptococcus Pneumoniae
  1. By Value
4. Drug-Resistant Campylobacter
  1. By Value
5. Drug-Resistant Neisseria Gonorrhea
  1. By Value
6. Drug-Resistant Salmonella
  1. By Value
7. Others
  1. By Value
By End Use
1. Introduction
  1. End Use By Value
2. Hospitals
  1. By Value
3. Diagnostic Laboratories
  1. By Value
4. Pharmaceutical & Biotechnology Companies
  1. By Value
5. Others
  1. By Value

North America Market Analysis

Introduction
By Technology
1. Introduction
  1. Technology By Value
2. Microbial Culture
  1. By Value
3. Immunoassay
  1. By Value
4. Polymerase Chain Reaction
  1. By Value
5. Next-generation Sequencing
  1. By Value
6. Mass Spectrometry
  1. By Value
7. Others
  1. By Value
By Pathogen
1. Introduction
  1. Pathogen By Value
2. Methicillin-Resistant Staphylococcus Aureus
  1. By Value
3. Drug-Resistant Streptococcus Pneumoniae
  1. By Value
4. Drug-Resistant Campylobacter
  1. By Value
5. Drug-Resistant Neisseria Gonorrhea
  1. By Value
6. Drug-Resistant Salmonella
  1. By Value
7. Others
  1. By Value
By End Use
1. Introduction
  1. End Use By Value
2. Hospitals
  1. By Value
3. Diagnostic Laboratories
  1. By Value
4. Pharmaceutical & Biotechnology Companies
  1. By Value
5. Others
  1. By Value
U.S.
1. By Technology
  1. Introduction
    1. Technology By Value
  2. Microbial Culture
    1. By Value
  3. Immunoassay
    1. By Value
  4. Polymerase Chain Reaction
    1. By Value
  5. Next-generation Sequencing
    1. By Value
  6. Mass Spectrometry
    1. By Value
  7. Others
    1. By Value
2. By Pathogen
  1. Introduction
    1. Pathogen By Value
  2. Methicillin-Resistant Staphylococcus Aureus
    1. By Value
  3. Drug-Resistant Streptococcus Pneumoniae
    1. By Value
  4. Drug-Resistant Campylobacter
    1. By Value
  5. Drug-Resistant Neisseria Gonorrhea
    1. By Value
  6. Drug-Resistant Salmonella
    1. By Value
  7. Others
    1. By Value
3. By End Use
  1. Introduction
    1. End Use By Value
  2. Hospitals
    1. By Value
  3. Diagnostic Laboratories
    1. By Value
  4. Pharmaceutical & Biotechnology Companies
    1. By Value
  5. Others
    1. By Value
Canada

Europe Market Analysis

Introduction
By Technology
1. Introduction
  1. Technology By Value
2. Microbial Culture
  1. By Value
3. Immunoassay
  1. By Value
4. Polymerase Chain Reaction
  1. By Value
5. Next-generation Sequencing
  1. By Value
6. Mass Spectrometry
  1. By Value
7. Others
  1. By Value
By Pathogen
1. Introduction
  1. Pathogen By Value
2. Methicillin-Resistant Staphylococcus Aureus
  1. By Value
3. Drug-Resistant Streptococcus Pneumoniae
  1. By Value
4. Drug-Resistant Campylobacter
  1. By Value
5. Drug-Resistant Neisseria Gonorrhea
  1. By Value
6. Drug-Resistant Salmonella
  1. By Value
7. Others
  1. By Value
By End Use
1. Introduction
  1. End Use By Value
2. Hospitals
  1. By Value
3. Diagnostic Laboratories
  1. By Value
4. Pharmaceutical & Biotechnology Companies
  1. By Value
5. Others
  1. By Value
U.K.
1. By Technology
  1. Introduction
    1. Technology By Value
  2. Microbial Culture
    1. By Value
  3. Immunoassay
    1. By Value
  4. Polymerase Chain Reaction
    1. By Value
  5. Next-generation Sequencing
    1. By Value
  6. Mass Spectrometry
    1. By Value
  7. Others
    1. By Value
2. By Pathogen
  1. Introduction
    1. Pathogen By Value
  2. Methicillin-Resistant Staphylococcus Aureus
    1. By Value
  3. Drug-Resistant Streptococcus Pneumoniae
    1. By Value
  4. Drug-Resistant Campylobacter
    1. By Value
  5. Drug-Resistant Neisseria Gonorrhea
    1. By Value
  6. Drug-Resistant Salmonella
    1. By Value
  7. Others
    1. By Value
3. By End Use
  1. Introduction
    1. End Use By Value
  2. Hospitals
    1. By Value
  3. Diagnostic Laboratories
    1. By Value
  4. Pharmaceutical & Biotechnology Companies
    1. By Value
  5. Others
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Technology
1. Introduction
  1. Technology By Value
2. Microbial Culture
  1. By Value
3. Immunoassay
  1. By Value
4. Polymerase Chain Reaction
  1. By Value
5. Next-generation Sequencing
  1. By Value
6. Mass Spectrometry
  1. By Value
7. Others
  1. By Value
By Pathogen
1. Introduction
  1. Pathogen By Value
2. Methicillin-Resistant Staphylococcus Aureus
  1. By Value
3. Drug-Resistant Streptococcus Pneumoniae
  1. By Value
4. Drug-Resistant Campylobacter
  1. By Value
5. Drug-Resistant Neisseria Gonorrhea
  1. By Value
6. Drug-Resistant Salmonella
  1. By Value
7. Others
  1. By Value
By End Use
1. Introduction
  1. End Use By Value
2. Hospitals
  1. By Value
3. Diagnostic Laboratories
  1. By Value
4. Pharmaceutical & Biotechnology Companies
  1. By Value
5. Others
  1. By Value
China
1. By Technology
  1. Introduction
    1. Technology By Value
  2. Microbial Culture
    1. By Value
  3. Immunoassay
    1. By Value
  4. Polymerase Chain Reaction
    1. By Value
  5. Next-generation Sequencing
    1. By Value
  6. Mass Spectrometry
    1. By Value
  7. Others
    1. By Value
2. By Pathogen
  1. Introduction
    1. Pathogen By Value
  2. Methicillin-Resistant Staphylococcus Aureus
    1. By Value
  3. Drug-Resistant Streptococcus Pneumoniae
    1. By Value
  4. Drug-Resistant Campylobacter
    1. By Value
  5. Drug-Resistant Neisseria Gonorrhea
    1. By Value
  6. Drug-Resistant Salmonella
    1. By Value
  7. Others
    1. By Value
3. By End Use
  1. Introduction
    1. End Use By Value
  2. Hospitals
    1. By Value
  3. Diagnostic Laboratories
    1. By Value
  4. Pharmaceutical & Biotechnology Companies
    1. By Value
  5. Others
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Technology
1. Introduction
  1. Technology By Value
2. Microbial Culture
  1. By Value
3. Immunoassay
  1. By Value
4. Polymerase Chain Reaction
  1. By Value
5. Next-generation Sequencing
  1. By Value
6. Mass Spectrometry
  1. By Value
7. Others
  1. By Value
By Pathogen
1. Introduction
  1. Pathogen By Value
2. Methicillin-Resistant Staphylococcus Aureus
  1. By Value
3. Drug-Resistant Streptococcus Pneumoniae
  1. By Value
4. Drug-Resistant Campylobacter
  1. By Value
5. Drug-Resistant Neisseria Gonorrhea
  1. By Value
6. Drug-Resistant Salmonella
  1. By Value
7. Others
  1. By Value
By End Use
1. Introduction
  1. End Use By Value
2. Hospitals
  1. By Value
3. Diagnostic Laboratories
  1. By Value
4. Pharmaceutical & Biotechnology Companies
  1. By Value
5. Others
  1. By Value
UAE
1. By Technology
  1. Introduction
    1. Technology By Value
  2. Microbial Culture
    1. By Value
  3. Immunoassay
    1. By Value
  4. Polymerase Chain Reaction
    1. By Value
  5. Next-generation Sequencing
    1. By Value
  6. Mass Spectrometry
    1. By Value
  7. Others
    1. By Value
2. By Pathogen
  1. Introduction
    1. Pathogen By Value
  2. Methicillin-Resistant Staphylococcus Aureus
    1. By Value
  3. Drug-Resistant Streptococcus Pneumoniae
    1. By Value
  4. Drug-Resistant Campylobacter
    1. By Value
  5. Drug-Resistant Neisseria Gonorrhea
    1. By Value
  6. Drug-Resistant Salmonella
    1. By Value
  7. Others
    1. By Value
3. By End Use
  1. Introduction
    1. End Use By Value
  2. Hospitals
    1. By Value
  3. Diagnostic Laboratories
    1. By Value
  4. Pharmaceutical & Biotechnology Companies
    1. By Value
  5. Others
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Technology
1. Introduction
  1. Technology By Value
2. Microbial Culture
  1. By Value
3. Immunoassay
  1. By Value
4. Polymerase Chain Reaction
  1. By Value
5. Next-generation Sequencing
  1. By Value
6. Mass Spectrometry
  1. By Value
7. Others
  1. By Value
By Pathogen
1. Introduction
  1. Pathogen By Value
2. Methicillin-Resistant Staphylococcus Aureus
  1. By Value
3. Drug-Resistant Streptococcus Pneumoniae
  1. By Value
4. Drug-Resistant Campylobacter
  1. By Value
5. Drug-Resistant Neisseria Gonorrhea
  1. By Value
6. Drug-Resistant Salmonella
  1. By Value
7. Others
  1. By Value
By End Use
1. Introduction
  1. End Use By Value
2. Hospitals
  1. By Value
3. Diagnostic Laboratories
  1. By Value
4. Pharmaceutical & Biotechnology Companies
  1. By Value
5. Others
  1. By Value
Brazil
1. By Technology
  1. Introduction
    1. Technology By Value
  2. Microbial Culture
    1. By Value
  3. Immunoassay
    1. By Value
  4. Polymerase Chain Reaction
    1. By Value
  5. Next-generation Sequencing
    1. By Value
  6. Mass Spectrometry
    1. By Value
  7. Others
    1. By Value
2. By Pathogen
  1. Introduction
    1. Pathogen By Value
  2. Methicillin-Resistant Staphylococcus Aureus
    1. By Value
  3. Drug-Resistant Streptococcus Pneumoniae
    1. By Value
  4. Drug-Resistant Campylobacter
    1. By Value
  5. Drug-Resistant Neisseria Gonorrhea
    1. By Value
  6. Drug-Resistant Salmonella
    1. By Value
  7. Others
    1. By Value
3. By End Use
  1. Introduction
    1. End Use By Value
  2. Hospitals
    1. By Value
  3. Diagnostic Laboratories
    1. By Value
  4. Pharmaceutical & Biotechnology Companies
    1. By Value
  5. Others
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Antimicrobial Resistance Diagnostics Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

bioMérieux SA
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Hoffmann-La Roche AG
Thermo Fisher Scientific Inc.
Abbott
Danaher
BD
QIAGEN N.V.
Sysmex Corporation
Bio-Rad Laboratories Inc.
Accelerate Diagnostics Inc.
Alifax S.r.l.
Lumos Diagnostics Holdings Pty Ltd
Molsid SAS
Genetic Signatures Limited
iFAST Diagnostics Ltd
Astek Diagnostics Inc.
OpGen Inc.
T2 Biosystems, Inc.
Others

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment